Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors

Abstract

Patients with haemophilia and inhibitors to factors VIII or IX require bypassing therapy. The primary safety concern of bypassing agents is thromboembolism; however, the incidence of thromboembolic adverse events (TAEs) in haemophilia patients with inhibitors remains poorly characterized. The aim of this study was to assess the incidence of TAEs following exposure to bypassing agents in patients with haemophilia. Using U.S. Medicaid database (2000–2010), we identified a cohort of 719 males (mean age: 10 years at cohort entry) with haemophilia A or B and use of either recombinant factor VIIa (rFVIIa) or activated prothrombin complex concentrate (aPCC). Patients were followed up until loss of insurance eligibility, end of study period, or the first occurrence of TAE. Exposure was assessed on as-treated basis, and outcomes were adjudicated through review of healthcare claims. During the observation of a total of 2,823 person-years (py; mean follow-up: 3.9 years), 22 TAEs were identified, leading to incidence rates of 4.2 events (95% confidence interval [CI]: 1.8–8.3) per 1,000 unexposed py; 15.4 events (95% CI: 6.7–30.3) per 1,000 aPCC-exposed py; 18.2 events (95% CI: 8.3–34.6) per 1,000 rFVIIa-exposed py; and 29.7 events (95% CI: 6.1–86.7) per 1,000 py of concomitant exposure to both agents. The results were consistent across sensitivity analyses. In conclusion, we found no difference in the rate of TAEs across agents, but the data are compatible with a possibly increased rate associated with a combination therapy, highlighting the need for continuing safety monitoring through prospective registries or observational data.

Keywords

disseminated intravascular coagulation - haemophilia - deep vein thrombosis - drug safety

• References

• 1 DiMichele DM. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis. Haemophilia 2006; 12 (Suppl. 06) 37-41 , discussion 41–42
• 2 Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. Inhibitors in haemophilia: pathophysiology. Haemophilia 2004; 10 (Suppl. 04) 146-151
• 3 Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 2006; 12 (Suppl. 06) 23-28 , discussion 28–29
• 4 Collins PW, Chalmers E, Hart DP. , et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160 (02) 153-170
• 5 Astermark J, Donfield SM, DiMichele DM. , et al; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109 (02) 546-551
• 6 Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14 (02) 287-294
• 7 Leissinger C, Gringeri A, Antmen B. , et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365 (18) 1684-1692
• 8 Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 2010; 16 (Suppl. 02) 16-23
• 9 Valentino LA. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia 2010; 16 (02) 263-271
• 10 Konkle BA, Ebbesen LS, Erhardtsen E. , et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5 (09) 1904-1913
• 11 Antunes SV, Tangada S, Stasyshyn O. , et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20 (01) 65-72
• 12 Leissinger CA. Advances in the clinical management of inhibitors in hemophilia A and B. Semin Hematol 2016; 53 (01) 20-27
• 13 Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2 (10) 1700-1708
• 14 Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8 (02) 83-90
• 15 Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10 (Suppl. 02) 10-16
• 16 O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295 (03) 293-298
• 17 Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363 (19) 1791-1800
• 18 Chambost H, Santagostino E, Laffan M, Kavakli K. ; ONE Registry Steering Committee on behalf of the investigators. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry. Haemophilia 2013; 19 (04) 571-577
• 19 Kesselheim AS, Gagne JJ. Strategies for postmarketing surveillance of drugs for rare diseases. Clin Pharmacol Ther 2014; 95 (03) 265-268
• 20 Daly L. Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. Comput Biol Med 1992; 22 (05) 351-361
• 21 Crystal S, Akincigil A, Bilder S, Walkup JT. Studying prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. Med Care 2007; 45 (10) (Suppl. 02) S58-S65
• 22 Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12 (04) 352-362
• 23 Neufeld EJ, Kessler CM, Gill JC, Wilke CT, Cooper DL. ; Htrs Investigators. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004–2008). Haemophilia 2011; 17 (04) 650-656
• 24 Holme PA, Glomstein A, Grønhaug S, Tjønnfjord GE. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience. Haemophilia 2009; 15 (03) 727-732
• 25 Gringeri A, Fischer K, Karafoulidou A, Klamroth R, López-Fernández MF, Mancuso E. ; European Haemophilia Treatment Standardisation Board (EHTSB). Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 2011; 17 (04) 630-635
• 26 López-Fernández MF, Altisent Roca C, Álvarez-Román MT. , et al. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemost 2016; 115 (05) 872-895
• 27 Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13 (03) 244-248
• 28 Teitel J, Berntorp E, Collins P. , et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13 (03) 256-263
• 29 Witmer CM, Huang YS, Lynch K, Raffini LJ, Shah SS. Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study. J Pediatr 2011; 158 (05) 820-825.e1